The company's financial position is increasingly vulnerable, evidenced by a current ratio that has plummeted from 8.70 in 2020Q4 to a critical 0.22 as of 2024Q4.
| Total Current Assets | 959.55K | 3.59M | 959.55K | 2.48M | 7.07M | 12.69M | 33.66M | 8.03M | 28.72M | 20.28M |
| Cash & Short-Term Investments | 874.24K | 3.45M | 874.24K | 2.01M | 1.99M | 8.5M | 31.88M | 6.25M | 13.02M | 18.22M |
| Cash Only | 874.24K | 3.45M | 874.24K | 2.01M | 1.88M | 8.13M | 3.5M | 5.19M | 12.01M | 16.25M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 102.48K | 236.62K | 28.38M | 1.06M | 1.01M | 1.97M |
| Accounts Receivable | 4.54K | 0 | 4.54K | 70.94K | 1.18M | 3.56M | 341.06K | 487.59K | 990.85K | 179.49K |
| Days Sales Outstanding | 227.83 | - | - | 60.03 | 332.53 | 842.9 | 136.57 | 332.55 | 943.17 | - |
| Inventory | 0 | 0 | 0 | 0 | 27.72K | 35.77K | 39.13K | 34.19K | 30.64K | 1.54M |
| Days Inventory Outstanding | 6.05 | - | - | - | 8.32 | 8.94 | 14.07 | 15.7 | 35.17 | 9.52K |
| Other Current Assets | 12.44K | 77.33K | 12.44K | 118.36K | 3.34M | 71.2K | 135.95K | 309.03K | 14.22M | 99.58K |
| Total Non-Current Assets | 15.17M | 15.1M | 15.17M | 18.16M | 13.8M | 9.22M | 10.57M | 15.92M | 16.35M | 11.28M |
| Property, Plant & Equipment | 0 | 0 | 0 | 1.85M | 3.17M | 4.03M | 5.38M | 7.09M | 4.26M | 346.59K |
| Fixed Asset Turnover | 0.40x | - | - | 0.23x | 0.41x | 0.38x | 0.17x | 0.08x | 0.09x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 147.35K | 752.71K | 880.26K | 964.86K | 1.31M | 1.41M | 1.47M |
| Long-Term Investments | 57.04M | 15.1M | 15.1M | 16.1M | 9.74M | 4.16M | 4.08M | 7.11M | 7.09M | 7.39M |
| Other Non-Current Assets | 71.82K | 0 | 71.82K | 71.82K | 127.3K | 149.18K | 149.18K | 59.83K | 119.67K | 2.06M |
| Total Assets | 16.13M | 18.69M | 16.13M | 20.64M | 20.87M | 21.91M | 44.23M | 23.95M | 45.07M | 31.56M |
| Asset Turnover | 0.03x | - | - | 0.02x | 0.06x | 0.07x | 0.02x | 0.02x | 0.01x | - |
| Asset Growth % | -40.09% | 15.88% | -21.85% | -1.09% | -4.75% | -50.47% | 84.65% | -46.86% | 42.82% | - |
| Total Current Liabilities | 4.34M | 4.59M | 4.34M | 2.1M | 12.5M | 4.38M | 3.87M | 2.67M | 12.18M | 1.33M |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40.14K | 0 |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | 46.07 | - |
| Short-Term Debt | 3.24M | 3.42M | 3.24M | 204.41K | 6.01M | 204.7K | 627.92K | 0 | 10.11M | 480K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.24M | 0 |
| Other Current Liabilities | 0 | 0 | 0 | -204.41K | 0 | -204.7K | -627.92K | 55.48K | 811.93K | 0 |
| Current Ratio | 0.22x | 0.78x | 0.22x | 1.18x | 0.57x | 2.90x | 8.70x | 3.00x | 2.36x | 15.24x |
| Quick Ratio | 0.22x | 0.78x | 0.22x | 1.18x | 0.56x | 2.89x | 8.69x | 2.99x | 2.35x | 14.09x |
| Cash Conversion Cycle | 233.88 | - | - | - | - | - | - | - | 932.27 | - |
| Total Non-Current Liabilities | 14.18K | 306K | 14.18K | 3.16M | 530.78K | 23.85K | 2.21M | 6.43M | 143.87K | 0 |
| Long-Term Debt | 0 | 0 | 0 | 3.06M | 500K | 0 | 2.01M | 6.33M | 0 | 0 |
| Capital Lease Obligations | 375.46K | 0 | 14.18K | 99.48K | 30.78K | 23.85K | 203.04K | 97.32K | 143.87K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 306K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 4.35M | 4.9M | 4.35M | 5.26M | 13.03M | 4.4M | 6.08M | 9.1M | 12.33M | 1.33M |
| Total Debt | 3.35M | 3.44M | 3.35M | 3.49M | 6.85M | 217.17K | 3.32M | 6.47M | 10.3M | 480K |
| Net Debt | 2.48M | -9.96K | 2.48M | 1.48M | 4.97M | -7.91M | -174.98K | 1.29M | -1.71M | -15.77M |
| Debt / Equity | 0.28x | 0.25x | 0.28x | 0.23x | 0.88x | 0.01x | 0.09x | 0.44x | 0.31x | 0.02x |
| Debt / EBITDA | -0.25x | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.18x | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -30.72x | -18.99x | -27.30x | -87.51x | - | -288.68x | 21.20x | -4.44x | -2.39x | - |
| Total Equity | 11.78M | 13.74M | 11.78M | 15.38M | 7.83M | 17.51M | 38.15M | 14.85M | 32.75M | 30.23M |
| Equity Growth % | 57.71% | 16.71% | -23.44% | 96.38% | -55.25% | -54.12% | 156.89% | -54.65% | 8.33% | - |
| Book Value per Share | 2.10 | 1.87 | 2.16 | 3.40 | 2.19 | 5.00 | 12.10 | 5.12 | 11.73 | 10.04 |
| Total Shareholders' Equity | 21.13M | 23.12M | 21.13M | 24.85M | 15.71M | 23.61M | 41.83M | 16.36M | 33.11M | 30.24M |
| Common Stock | 55 | 80 | 55 | 53 | 35.71M | 35.64M | 34.02M | 29.04M | 28.98M | 27.86M |
| Retained Earnings | -72.43M | -73.79M | -72.43M | -68.16M | -65.34M | -55.54M | -30.49M | -37.56M | -17.38M | -2.55M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 89.16K | -92.31K | 89.16K | -10.62K | 33.81K | -2.02K | 53.3K | -5.55K | -1.48M | -367.78K |
| Minority Interest | -9.36M | -9.37M | -9.36M | -9.46M | -7.88M | -6.1M | -3.68M | -1.51M | -368.53K | -14.04K |
Critical liquidity depletion
As reported in recent financial filings, Aptorum's total assets have declined from a peak of $44.2 million in 2020Q4 to just $16.1 million by 2024Q4, reflecting a persistent contraction that underscores the company's inability to replenish its resource base while funding ongoing clinical development activities.
The consistent downward trend in total assets suggests that the company is consuming its capital base to sustain operations rather than growing its underlying value. This trajectory indicates that the business model is currently unable to generate the internal returns necessary to offset the steady depletion of its balance sheet.
Based on the most recent quarterly data, Aptorum's current ratio has plummeted to 0.22, a stark deterioration from the 8.70 ratio observed in 2020Q4, which indicates that the company's liquid assets are now severely insufficient to cover its near-term liabilities and ongoing operational burn requirements.
A current ratio below 1.0 suggests that the company faces significant challenges in meeting its short-term obligations without immediate external intervention. Investors should monitor this metric closely, as the current liquidity position provides virtually no margin of safety against unexpected clinical or operational setbacks.
According to historical balance sheet data, accumulated deficits have ballooned to $72.4 million as of 2024Q4, effectively eroding the company's equity base and signaling that years of R&D investment have yet to translate into sustainable value creation or a path toward positive retained earnings.
The persistent growth of the accumulated deficit highlights the high cost of the company's multi-asset pipeline strategy. This trend suggests that shareholders have borne the brunt of the company's inability to reach commercial milestones, with equity quality remaining highly sensitive to further dilutive financing needs.
While the company's debt-to-equity ratio of 0.28 appears modest, as indicated by recent financial statements, this figure likely reflects a lack of access to traditional credit markets rather than a position of financial strength, given the company's pre-revenue status and limited cash reserves.
Investors should be cautious not to interpret low leverage as a sign of financial health in this context. The reliance on equity rather than debt for funding suggests that the company's capital structure is driven by necessity, potentially masking the true cost of capital and the ongoing risk of shareholder dilution.
Quick answers to the most common questions about buying APM stock.
As of 2025, Aptorum Group Limited (APM) had total assets of $18.7M including $3.6M in current assets.
Aptorum Group Limited (APM) carries total debt of $3.4M, offset by $3.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Aptorum Group Limited (APM) has total shareholders' equity (book value) of $23.1M ($1.87 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Aptorum Group Limited (APM) reported a current ratio of 0.78x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.